Telehealth GLP-1 prescriptions
A large telehealth clinic that sells compounded and brand-name GLP-1 treatments for weight loss alongside sexual health, longevity and hair products. It lists brand-name and compounded options side by side with prices.
We may earn a commission if you buy through the links to Shed on this page, at no extra cost to you. That does not change how we grade or rank it, and Shed did not write or approve this review.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Compounded semaglutide and tirzepatide, Wegovy, Zepbound, oral GLP-1 forms, MIC+B12, plus sexual health, longevity and hair treatments.
From $159/month
From $239/month
From $349/month
From $229/monthEverything here is a prescription service that starts with a licensed clinician's review of your own health information. Compounded medications are made by a pharmacy against a prescription and are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality. This entry describes what the brand offers and what we could check. It is not medical advice and not a recommendation to use it.
Every telehealth brand we rank gets the same five checks, read from its public pages on September 24, 2026. "Not met" means we did not find it, or the terms say otherwise, on the pages we could read. Price and commission play no part.
The banner and the product page show different prices ($159 against $249 for semaglutide).
The homepage names its physicians, including Dr. Asad Niazi and Dr. Abhi Patel.
Its terms name six pharmacies: Strive, Promise, DCA, Everwell, Custom Ivy and Boothwyn.
A 120-day guarantee is published, but it requires a set list of check-ins and appointments.
No warning letter under this name in FDA's public database on September 24, 2026. One pharmacy it names, Boothwyn, has its own; see the flags.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
That is the banner across the site. The weight-loss product page on the same site lists compounded semaglutide 'starting at $249/month' and tirzepatide 'starting at $349/month'. We could not reconcile the two, so check the price at checkout for your dose.
Where the vendor states thisThe terms say you must lose 5% of your baseline weight or reach your goal weight within 120 days while completing four monthly coaching appointments, eight weight entries, sixty daily check-ins and all provider follow-up forms. We confirmed this ourselves.
Where the vendor states thisThe site says the totals come from self-reported member data and that the 9.8% average weight loss it shows is from VIP member data. Neither is an independent outcome study.
Where the vendor states thisFDA does not review compounded drugs for safety, effectiveness or quality before they are sold. In 2026 FDA warned 30 telehealth companies over claims implying sameness with approved drugs, and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, so the legal footing of this category can change.
The banner shows semaglutide from $159 and tirzepatide from $239, while the weight-loss page shows $249 and $349. The lower figures may be promotions, but the page does not say so.
The 120-day guarantee depends on eligibility and adherence, and the results shown are self-reported by members.
FDA letter 717525 to Boothwyn Pharmacy, dated January 16, 2026, says it made sterile drugs under insanitary conditions and released semaglutide and tirzepatide injections that were subpotent, and that it stopped GLP-1 production. Shed's terms list Boothwyn among six partner pharmacies. We have not confirmed whether Shed still uses it.
The site shows both $159 and $249. The lower figure is a banner price and the higher one is on the product page. Confirm your dose and plan at checkout.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 25, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
